Leukemia Fighters
- Company typePrivate
- Founded-
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
Leukemia Fighters firmographics
Firmographics- Name
- Leukemia Fighters
- Website
- https://leukemia-fighters.net
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Leukemia Fighters industry classification
Industry- Product category
- Hematology Oncology Services
- NAICS
- Other Ambulatory Health Care Services (6219), Ambulatory Health Care Services (621)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)
- akta.pro industry
- Hematologic Oncology (Leukemia/Lymphoma/Myeloma)Medical Hematology (Benign Hematology)Bone Marrow & Stem Cell Transplant (BMT/HSCT)
Keywords
Where Leukemia Fighters is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Leukemia Fighters business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
Revenue model
- Patient Care Services: Revenue generated from diagnostic, treatment, and monitoring services for leukemia patients across inpatient and outpatient settings, billed through insurance and institutional healthcare payment systems
- Clinical Trial Participation: Revenue and research funding from participation in clinical trials for FDA drug development, including support from pharmaceutical partners and research grants
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Leukemia Fighters product offering
Product offeringCore offering
The Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital provides comprehensive diagnostic, treatment, and clinical trial services for adult patients with acute leukemias (AML, ALL), chronic leukemias (CML, CLL), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and bone marrow failure diseases. The program offers same-day appointments for newly diagnosed patients, multidisciplinary consultation, second opinions, and access to an extensive clinical trials portfolio, including immunotherapy, CAR-T cell therapy, and stem cell transplantation.
Product overview
The Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital is a unified clinical care offering comprising core hematology/oncology treatment services for acute and chronic leukemias, supported by digital health infrastructure (Weill Cornell Connect, Video Visits, Mobile App), same-day appointment access for newly diagnosed patients, and an extensive clinical trials portfolio for various patient populations. The program is led by internationally recognized physicians and participates in FDA drug development for leukemia treatments.
Differentiator
Problem solved
Functional benefit
Products and services
- Leukemia Program Clinical Services Comprehensive diagnostic evaluation, treatment planning, and ongoing care for adult patients with acute leukemias, chronic leukemias, MDS, MPN, and bone marrow failure diseases, delivered by a multidisciplinary team of hematologist-oncologists.
- Same-Day Appointments for Newly Diagnosed Patients Expedited consultation service that allows newly diagnosed leukemia patients to be evaluated by program specialists on the same day they contact the program, addressing urgent diagnostic and treatment needs.
- Leukemia Clinical Trials Portfolio Portfolio of clinical trials offering leukemia patients access to investigational therapies including immunotherapy approaches, CAR-T cell therapy, novel targeted agents, and stem cell transplantation procedures.
- Weill Cornell Connect Digital health platform that allows patients to communicate with their care team, manage appointments, request prescription refills, and access health records online.
- Video Visits Remote consultation service enabling patients to meet with their leukemia care team via secure video connection for follow-up visits and consultations.
Companies that use Leukemia Fighters
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Leukemia Fighters technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Leukemia Fighters partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NewYork-Presbyterian HospitalcoreThe Leukemia Program operates as a joint initiative between Weill Cornell Medicine and NewYork-Presbyterian Hospital, providing comprehensive leukemia care within an academic medical center setting. The partnership combines clinical care, research, and education capabilities.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Leukemia Fighters competitors and assessment
Company assessmentBroad incumbents
- Memorial Sloan Kettering Cancer Center: One of the world's premier cancer centers operating a major leukemia service that competes directly for complex hematologic malignancy patients and clinical trial enrollment. MSKCC's program is comparable in academic standing, clinical trial portfolio, and physician reputation.
- City of Hope Comprehensive Cancer Center: NCI-designated cancer center with major hematology program including hematopoietic stem cell transplantation. Comparable in offering comprehensive leukemia care and clinical trials for newly diagnosed and relapsed patients.
- Moffitt Cancer Center: NCI-designated comprehensive cancer center operating a malignant hematology program with significant clinical trial activity. Competes for complex leukemia cases and academic medical center referrals.
- Fred Hutchinson Cancer Center: Seattle-based NCI-designated cancer center historically renowned for bone marrow transplantation and leukemia research. Strong overlap in clinical trial participation for leukemia therapies and bone marrow failure diseases.
- Roswell Park Comprehensive Cancer Center: NCI-designated comprehensive cancer center in Buffalo with a leukemia and hematologic malignancies service offering clinical trials and specialized treatments. Comparable academic model with similar trial-focused positioning.
- Ohio State University Comprehensive Cancer Center: NCI-designated academic cancer center with a substantial leukemia program known for clinical trial participation in hematologic malignancies. Comparable in academic affiliation and trial portfolio scope.
- MD Anderson Cancer Center: Leading NCI-designated comprehensive cancer center with a large leukemia program that participates in pivotal trials for FDA-approved leukemia drugs. Operates as a direct competitor for relapsed/refractory patients and clinical trial leadership.
- Dana-Farber Cancer Institute: Harvard-affiliated NCI-designated cancer center with a renowned leukemia program known for clinical research and novel therapy development. Comparable in academic standing, trial participation, and physician reputation in hematologic malignancies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Leukemia Fighters social profiles
Digital presenceLeukemia Fighters financial estimates
Financial estimateRevenue estimate
Valuation estimate
Leukemia Fighters leadership team
Management profileNumber of profiles
Profiles1 record
Leukemia Fighters funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Leukemia Fighters M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Leukemia Fighters
What does Leukemia Fighters do?
The Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital provides comprehensive diagnostic, treatment, and clinical trial services for adult patients with acute leukemias (AML, ALL), chronic leukemias (CML, CLL), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and bone marrow failure diseases. The program offers same-day appointments for newly diagnosed patients, multidisciplinary consultation, second opinions, and access to an extensive clinical trials portfolio, including immunotherapy, CAR-T cell therapy, and stem cell transplantation.
When was Leukemia Fighters founded?
Leukemia Fighters was founded in -1. It employs 1 to 10 people.
Where is Leukemia Fighters based?
Leukemia Fighters is headquartered in New York, United States, in the North America region.
How does Leukemia Fighters make money?
Two revenue lines are on record. Patient Care Services are the primary driver. The others are clinical Trial Participation.
Who are Leukemia Fighters's main competitors?
Broad incumbents on record are Memorial Sloan Kettering Cancer Center, City of Hope Comprehensive Cancer Center, Moffitt Cancer Center, Fred Hutchinson Cancer Center, Roswell Park Comprehensive Cancer Center, Ohio State University Comprehensive Cancer Center, MD Anderson Cancer Center and Dana-Farber Cancer Institute.
Does Leukemia Fighters have an API?
No public API is recorded for Leukemia Fighters.
What industry is Leukemia Fighters in?
Leukemia Fighters's product category is Hematology Oncology Services. Its primary akta.pro industry code is HLAKAFAD, Hematologic Oncology (Leukemia/Lymphoma/Myeloma), with a secondary code of HLAKAFAA, Medical Hematology (Benign Hematology). Its NAICS code is 6219 and its SIC code is 8011.